Tandem Diabetes Care filings document the company’s insulin delivery business, Nasdaq-listed common stock, operating results, governance matters, and capital structure. Recent 8-K reports furnish quarterly and annual financial results, guidance-related disclosures, and product or regulatory events tied to its diabetes technology portfolio.
The filing record also includes proxy materials for annual meeting voting, director elections, executive compensation, equity awards, and board committee matters. Material-event filings describe the company’s completed 0.00% convertible senior notes offering, related indenture terms, and FDA clearance for the SteadiSet wearable infusion set.
Tandem Diabetes Care, Inc. reported second quarter 2026 results with worldwide sales of $254.6 million, a 6% increase from $240.7 million, including U.S. sales of $179.3 million and international sales of $75.3 million. Pump shipments exceeded 33,000 units worldwide, with about 22,000 in the U.S. and 11,000 internationally.
Gross profit was $144.8 million and gross margin improved to 57%, up 460 basis points from 52% a year earlier. GAAP operating loss narrowed to $13.8 million, or negative 5% of sales, from $51.8 million, and GAAP net loss was $21.2 million, or $0.31 per share, compared with $52.4 million, or $0.78 per share. Adjusted EBITDA turned positive at $6.4 million, or 3% of sales.
For full-year 2026, Tandem reaffirmed sales guidance of approximately $1.065 billion to $1.085 billion, with U.S. sales of $730 million to $745 million and international sales of $335 million to $340 million. It expects gross margin of about 56% to 57% and adjusted EBITDA margin of about 5% to 6%, and now anticipates approximately $85 million of non-cash charges. Strategically, the company submitted a 510(k) for Tandem Mobi tubeless capability, gained new FDA clearances and CE Marks for Control-IQ+ in additional indications, expanded sensor compatibility with Dexcom G7 and Abbott FreeStyle Libre 3 Plus, and began the international commercial rollout of Tandem Mobi.
Voya Financial, Inc. filed an amended Schedule 13G reporting its beneficial ownership of common stock of Tandem Diabetes Care, Inc. Voya reports beneficial ownership of 149,088 shares of Tandem’s common stock, representing 0.2% of the outstanding class.
Voya states it has sole voting power and sole dispositive power over all 149,088 shares, with no shared voting or dispositive power. The filing notes that this ownership represents 5 percent or less of the class and is reported by Voya as the ultimate parent of certain wholly owned subsidiaries listed on an exhibit.
Tandem Diabetes Care EVP & Chief Operating Officer Jean-Claude Kyrillos reported equity compensation activity. On July 15, 2026, 3,636 restricted stock units converted into common stock, bringing his direct holdings to 31,741 shares. To satisfy tax withholding on the vesting, the company withheld 1,926 shares at $15.28 per share; no shares were sold in the market. After this vesting, 14,545 RSUs from a July 2024 grant under the 2023 Long-Term Incentive Plan remain outstanding.
Tandem Diabetes Care submitted a Rule 144 notice to sell 361 shares of its common stock represented by Restricted Stock Units, with an issuer-designated sale method dated 06/15/2026.
Separately, the filing discloses a 10b5-1 sale by Mark Novara of 266 shares on 05/19/2026, reported in the "Securities Sold During The Past 3 Months" section. The filing lists broker details as Morgan Stanley Smith Barney LLC.
Tandem Diabetes Care executive Elizabeth Anne Gasser reported gift transfers of company common stock. On June 2, she disposed of a total of 14,320 shares as bona fide gifts, including a transfer from her direct holdings to The Gasser Family Trust dated September 1, 2011 for no consideration. After these transactions, the trust holds 33,109 shares indirectly with Gasser as co-trustee, and her reported direct common stock holdings are 0 shares. These are non-market, estate-planning type movements rather than open-market sales.
Sheridan John F reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care reported that President and CEO John F. Sheridan received a grant of 191,103 restricted stock units (RSUs). Each RSU represents the right to receive one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.
One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, encouraging longer-term alignment between the CEO and shareholders.
Gasser Elizabeth Anne reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care Inc. reported that EVP and Chief Strategy Officer Elizabeth Anne Gasser received a grant of 29,136 restricted stock units (RSUs). Each RSU represents a contingent right to one share of common stock or cash, at the company’s discretion, under the 2023 Long-Term Incentive Plan.
All 29,136 RSUs are held directly and bring her reported RSU holdings in this award to 29,136 units. One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to the plan’s terms. This is a compensation-related equity award, not an open-market purchase or sale.
Vosseller Leigh reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive vice president and chief financial officer Leigh Vosseller received a grant of 62,657 restricted stock units (RSUs) under the company’s 2023 Long-Term Incentive Plan. Each RSU represents a contingent right to receive one share of common stock or cash at the company’s discretion.
One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to plan terms and continued eligibility. This is a stock-based compensation award, not an open-market share purchase or sale.
Kyrillos Jean-Claude reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive vice president and chief operating officer Jean-Claude Kyrillos received a grant of 29,136 restricted stock units (RSUs). Each RSU represents a contingent right to one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan.
One-third of these RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, subject to plan terms. Following this grant, Kyrillos directly holds 29,136 RSUs linked to common stock.
Morrison Susan reported acquisition or exercise transactions in this Form 4 filing.
Tandem Diabetes Care executive Susan Morrison received a grant of 29,136 restricted stock units as part of equity compensation. Each RSU represents a right to receive one share of common stock or cash under the company’s 2023 Long-Term Incentive Plan. One-third of the RSUs will vest on May 29, 2027, with the remaining units vesting in eight equal quarterly installments on the 15th of the month thereafter, contingent on plan terms and continued service. Following this award, Morrison holds 29,136 RSUs directly.